NCT06299982View on ClinicalTrials.gov

An Phase III Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With PsO

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

750

Participants

Timeline

Start Date

May 15, 2024

Primary Completion Date

January 30, 2025

Study Completion Date

March 20, 2025

Conditions

Plaque Psoriasis Patients

Interventions

DRUG

608 Q2W

608 160 mg at week 0 + 80 mg Q2W (5 cycles)

DRUG

608 Q4W

608 160 mg Q4W (3 cycles)

All Listed Sponsors

lead

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

INDUSTRY